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Abstract 
Previously, it was found that 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione 
(TP-315) effectively protects mice from maximal electroshock-induced seizures. The aim of this 
study was to determine possible interactions between TP-315 and different molecular targets, i.e. 
GABAA receptors, voltage-gated sodium channels, and human neuronal α7 and α4β2 nicotinic 
acetylcholine receptors. The influence of TP-315 on the viability of human hepatic HepG2 cells was 
also established using PrestoBlue and ToxiLight assays. It was found that the anticonvulsant activity 
of TP-315 results (at least partially) from its influence on voltage-gated sodium channels (VGSCs). 
Moreover, the title compound slightly affected the viability of human hepatic cells. 
Key words: Sodium channels; [3H]-batrachotoxin; patch-clamp; cell viability assays. 
Introduction 
Epilepsy is a neurological disorder in which 
abnormal excessive and/or hypersynchronous 
neuronal activity occurs causing seizures or other 
symptoms, like temporary confusion, loss of 
consciousness or awareness, unusual sensations, etc. 
The main aim of treatment of epilepsy is to obtain a 
seizure-free state or to reduce seizure frequency in 
patients. The main form of treatment of epilepsy in 
humans is the administration of anti-epileptic drugs 
(AEDs). However, about one-third of patients with 
epilepsy suffer from seizures that cannot be fully 
controlled with currently available AEDs [1, 2]. 
Simultaneously, it is well known that dose-dependent 
and reversible adverse effects of AEDs are common, 
especially in patients treated with polytherapy [3]. 
Therefore, there is an immense demand for the 
development of novel anticonvulsant drugs, 
especially such ones that offer better tolerability with 
limited adverse effects. 
Recently, the screening tests performed in our 
laboratory revealed that 5-(3-chlorophenyl)-4--
hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315; 
Fig. 1) produced evident anticonvulsant action in the 
maximal electroshock-induced seizure model in mice 
(Fig. 2) [4]. Moreover, the triazole derivative TP-315 
appeared to have a beneficial protective index.  
However, until now nothing was known about 
the mechanism(s) involved in the anticonvulsant 
activity of TP-315. Molecular target identification is 








candidates [5]. Nonetheless, even such molecules that 
strongly interact with their biological target(s) can fail 
to become successful drug because of safety concerns. 
So, it is important to evaluate the potential toxicity in 
early stages of drug development. The aim of the 
present study was to examine the effect of TP-315 on 
different molecular targets in the central nervous 
system, i.e. GABAA receptors, voltage-gated sodium 
channels, and human neuronal α7 and α4β2 nicotinic 
acetylcholine receptors. Moreover, the cellular toxicity 
of TP-315 towards human hepatic cells was 
investigated using two types of viability measuring 
assays, i.e. PrestoBlue and ToxiLight assays.  
 
Figure 1. Chemical structure of TP-315 
 
 
Figure 2. Time-course and dose-response effects of TP-315 in the maximal electroshock-induced seizure (MES) and chimney tests in mice. Left panel: 
Dose–response function for the anticonvulsant (protective) activity (A) and acute neurotoxic impairment of motor coordination (B) of TP-315 in the MES and 
chimney tests. Each data point (n=8 mice/data point) represents percent of mice protected from the MES test (A), or percent of mice with impairment of motor 
coordination in the chimney test (B), at a given dose (in mg/kg) of TP-315 in various pretreatment times (15, 30, 60 and 120 min). Sigmoidal curves are the result of 
a least squares fit of dose-response function for the tested compound (TP-315). Points of intersections with the dashed line at 50% correspond to approximate ED50 
values (A) or TD50 values (B) of TP-315. Right panel: Columns represent median effective doses (ED50 in mg/kg ± S.E.M.) of TP-315 (A), that protect 50% of animals 
tested against MES-induced seizures in mice, or median toxic doses (TD50 in mg/kg ± S.E.M.) of TP-315 (B), that impair motor coordination in 50% of the mice 
subjected to the chimney test. The log-probit method was used for calculating the ED50 and TD50 values of TP-315 at 4 various pretreatment times (15, 30, 60 and 120 
min).  







Electrophysiology experiments were carried out 
on a QPatch16X automatic patch clamp platform 
(Sophion Biosciences). HEK293 cells, stably 
expressing the α1β2γ2 subunits of the human GABAA 
receptor were cultured using standard procedures. 
On the day of experiment cells were collected from 
the culture flask using Detachin solution (VWR) and 
resuspended in serum-free media. Cell suspension 
was placed in the magnetic stirred tube, located 
onboard the automated electrophysiology instrument 
and allowed to recover for 60 minutes at room 
temperature. In the next step, cells were automatically 
transferred to a built-in centrifuge, spun down and 
washed in extracellular Ringer’s solution. Cells were 
applied to the pipetting wells of a disposable 
16-channel planar patch chip plates (QPlate 16X, with 
10 patch clamp holes per measurement site) and 
gigaseals were formed upon execution of a combined 
suction/voltage protocol. Further suction lead to 
whole-cell configuration. GABAA receptor chloride 
currents were recorded for 7s after each addition of 
compound. During whole-cell recording, the holding 
potential was set to -90 mV. Recordings were 
performed at room temperature. Extracellular 
solution consisted of (in mM): 2 CaCl2, 1 MgCl2, 10 
HEPES, 4KCl, 145 NaCl, 10 glucose (pH 7.4, 300 
mOsm) and intracellular solution contained (in 
mM):140 CsF, 1 EGTA, 5 CsOH, 10 HEPES, 20 NaCl 
(pH 7.2, 320 mOsm). 
In the agonist assays, the sequential application 
of: 10 μM γ-aminobutyric acid (GABA, reference 
agonist at concentration close to half maximal 
effective concentration); 10 μM tested compound 
(TP-315) and second addition of 10 μM GABA was set 
up in the instrument software. The interval between 
additions of particular compounds was at least 60s. 
Typically 5 μl of ligand was added to the cells, which 
was followed after 3s by washout with extracellular 
solution (two times 5 μl).  
In the allosteric modulator/antagonist 
dose-response mode (simultaneous addition of GABA 
and tested compound) first 10 μM GABA application 
was followed by 6 additions of increasing 
concentrations of tested compound (0.001-100 μM) in 
combination with 10 μM GABA. In this setup, cells 
were preincubated with potential allosteric 
modulator/antagonist alone for at least 50 s, before 
the addition of combination with agonist. 
Concentration of reference agonist used in this study 
(being close to EC50 value) was chosen during method 
validation process and enabled the detection of both 
antagonist (e.g. bicuculline) and positive allosteric 
modulator (e.g. zolpidem) activity in single setup [6]. 
Data were analyzed using QPatch Assay 
Software (v5.0, Sophion Biosciences) and representthe 
mean of at least three experiments carried out on 
distinct cells. Validation criteria for eachexperiment 
were: current amplitude evoked by addition of GABA 
higher than 500 pA anddifference between cells 
response to both GABA applications in agonist mode 
not higher than 25%. 
Radioligand binding assay for Na+ channel - site 
2 using [3H]batrachotoxin 
Radioligand binding assay was performed 
according to the method of Callaway et al. [7] with 
slight modifications. Rat cerebral cortex was weighed 
and homogenised at concentration of 10% (w/v) in 
ice-cold 0.32 M sucrose, 10 mM phosphate buffer (pH 
7.4) using an ULTRA TURRAX homogeniser. The 
homogenate was centrifuged at 1000 x g for 10 min 
(0-4oC). Collected supernatant was centrifuged at 40 
000 x g for 45 min (0-4oC) to obtain membrane 
fraction. The resulting pellet was resuspended in 
incubation buffer containing (mM): 50 Tris base, 50 
HEPES, 130 choline chloride, 5.4 KCl, 0.8 MgSO4 and 
5.5 glucose (pH 7.4). 300 µl of the tissue suspension 
(300 µg/well) containing LQ scorpion venom (10 
µg/well), 50 µl of [3H]-BTX solution (final conc. 10 
nM, spec. act. 38.6 Ci/mmol, PerkinElmer) and 50 µl 
of the tested compounds were incubated at 37ºC for 1 
h. The incubation was terminated by rapid filtration 
over glass fiber filters (FilterMate B, PerkinElmer) 
using 96-well harvester (PerkinElmer). Eight rapid 
washes with 500 µl of ice-cold 50 mM Tris-HCl buffer, 
pH 7.4, were performed. Veratridine (300 μM) was 
used to define nonspecific binding. 
Filter mates were dried at 37°C in forced-air 
incubator and solid scintillator (MeltiLex, 
PerkinElmer) was then melted on them at 100°C for 5 
minutes. The radioactivity on the filters was 
measured in MicroBetaTriLux 1450 scintillation 
counter (PerkinElmer).Each compound was tested in 
a screening assay at final concentration of 100 µM. 
Results were expressed as percent inhibition of 
[3H]-batrachotoxin binding. Then compound TP-315, 
qualified for dose-response binding experiments, was 
tested in 8 concentrations ranging from 300 to 0.1 µM. 
Interaction of TP-315 with orthosteric sites of 
human α7 and human α4β2 nicotinic 
acetylcholine receptors (nAChRs) 
Reagents 
See Table A. 
 




Table A. Reagents 





Protease inhibitors cocktail 
Sodium azide (NaN3) 
Trizma base 
Trizma hydrochloride 
Potassium chloride (KCl) 
Baxter (Lublin, Poland) 
Sodium chloride (NaCl) 
Di-sodium hydrogen phosphate 
(NaH2PO4) 
POCH (Gliwice, Poland) 




Fetal bovine serum (FBS) 
Life Technologies 
Trypsin/EDTA 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Ham’s F-12 nutrient mixture 
Hygromycin B 
Geneticin (G-418 sulfate) 
 
Membrane preparation 
nAChRs binding experiments were performed 
on membranes from HEK-293 and SHSY5Y cells 
stably transfected with genes encoding hα4β2 and hα7 
nAChRs, respectively. Method of Arias et al. was used 
to obtain membranes and perform binding assay [8]. 
HEK293-hα4β2 cells were maintained in 1:1 
mixture of Dulbecco’s Modified Eagle Medium 
(DMEM) and Ham’s F-12 nutrient mixture 
supplemented with 10% fetal bovine serum (FBS), 200 
µg/ml G-418 and 200 µg/ml hygromycine B. 
SHSY5Y-hα7 were cultured in DMEM supplemented 
with 10% FBS and 200 µg/ml G-418. Cells were 
cultured for approximately 3 weeks in suspension on 
nontreated Petri dishes, then gently scraped and 
centrifuged at 500 x g for 5 min. Cells were then 
homogenized in binding saline buffer (50 mM 
Tris-HCl, pH 7.4 containing 120 mM NaCl, 5 mM KCl, 
2 mM CaCl2, 1 mM MgCl2) suplemented with a 
cocktail of protease inhibitors and 0.025% sodium 
azide and centrifuged at 10 000 rpm for 30 min at 4°C. 
The pellet was finally resuspended in binding saline 
buffer containing 20% sucrose. Aliquotes of AChR 
membranes were stored at -80°C.  
Radioligand binding assay 
Radioligand binding assay was performed in 
96-well plate format. AChR membranes (1 mg/ml), 
were suspended in binding saline buffer containing 10 
nM [3H]epibatidine and preincubated for 10 min at 
room temperature following the addition of TP-315. 
Nonspecific binding was determined in the presence 
of 1 µM (±)-epibatidine. After 90 min incubation at 
room temperature, the AChR-bound radioligand was 
separated from the free [3H]epibatidine by a filtration 
assay using a 96-sample harvester system with GF/B 
Whatman filters, previously soaked with 0.5% 
polyethylenimine for 30 min. The bound radioactivity 
was determined using the MicroBetaTriLux 
scintillation counter (Perkin Elmer). 
Cell viability and cytotoxicity assays 
Cell culture 
The human hepatocellular carcinoma cells 
(HepG2) were obtained from the ATCC (HB-8065). 
The cells were thawing according to the 
manufacturer's protocol form ATCC. HepG2 cells are 
cultivated in Eagle's Minimum Essential Medium 
(EMEM, ATCC) supplemented with 10% heat 
inactivated fetal bovine serum (ATCC), with added 
100 IU/ml penicillin (ATCC) and 100 µg/ml 
streptomycin (ATCC). The cells were passaged three 
times a week, until they reached confluence. HepG2 
cells culture were carried out in accordance with basic 
techniques of cell culture in sterile conditions. Cells 
were cultured in flasks with an area of 175 cm2, and 
incubated at 37°C, 5% CO2. For the test of compounds 
with the HepG2 cells line, hepatocytes were seeded on 
96-well culture plate at a density of 2x104 cells per 
well in fresh medium. Cells grew for 24 hours in the 
incubator (37°C, 5% CO2) before performing 
experiments. 
Sample preparation 
TP-315 was dissolved in dimethyl sulfoxide 
(DMSO) with stock concentrations of 10 mM. The 
compounds were incubated for 5 minutes with 
ultrasound in a water bath. From the stock, dilutions 
were prepared in phosphate buffered saline (PBS). All 
experiments were performed in triplicates, in two 
independent experiments. 
PrestoBlue assay 
Cell viability was measured using the PrestoBlue 
reagent (Invitrogen). PrestoBlue reagent is a 
resazurin-based solution that functions as a cell 
viability indicator. Metabolically active cells are 
capable of reducing the PrestoBlue reagent, with the 
colorimetric changes used as an indicator to quantify 
the viability of cells in culture. This change can be 
determined by measuring the fluorescence. After 24 
hours of incubation with the compounds the 
PrestoBlue reagent was added to wells of a microplate 
in an amount equals to one tenth of the remaining 
medium volume. After 15 minutes of incubation at 
37°C, the fluorescence intensity (EX 530 EM 580 nm) 




was measured in a plate reader (POLARstar Omega, 
BMG Labtech). Viability values were calculated as a 
percentage of live cells with respect to the control 
sample (DMSO). The negative control was medium 
without cells. 
ToxiLight assay 
The bioluminescent ToxiLight bioassay (Lonza) 
is a cytotoxicity highly sensitive assay designed to 
measure cell membrane damage. It quantitatively 
measures the release of Adenylate Kinase (AK) from 
the membranes of damaged cells. AK is a protein 
presented in all eukaryotic cells, which is released into 
the culture medium when cells die. The enzyme 
actively phosphorylates ADP and the resultant ATP is 
then measured using the bioluminescent firefly 
luciferase reaction with the ToxiLight reagent. The 
emitted light intensity expressed as a RLU value is 
linearly related to the adenylate kinase activity. After 
24h of treatments, 5 µl of the clear fluid above 
sediment was transferred into 384-well plate (Perkin 
Elmer). Then 20 μl of the Adenylate Kinase Detection 
Reagent (AKDR) was added. As a positive control for 
lysis 10% Triton X- 100 (Sigma-Aldrich) in growth 
medium is used, the negative control is growth 
medium alone. The luminescence was measured in a 
plate reader (POLARstar Omega, BMG Labtech) after 
5 minutes of incubation. The results were expressed as 
a percentage of positive control, which corresponded 




dihydro-3H-1,2,4-triazole-3-thione (TP-315) on 
the GABAA receptor chloride currents 
5-(3-Chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4
-triazole-3-thione (TP-315) in 10 µM concentration was 
not able to evoke GABAA receptor chloride current, 
when added directly to QPlate measurement site 
containing recombinant HEK-293 cells in whole-cell 
configuration (Fig. 3A). Thus, it can be stated that 
TP-315 lacks significant efficacy at GABAA receptors. 
Moreover, no potentiation, neither blockade of 
GABA-evoked currents was observed when GABA 
(10 µM) was used in combination with different 
concentrations of TP-315 (i.e. 0.001 µM – 100 µM) (Fig. 
3B). Therefore, it can be concluded that TP-315 does 
not possess allosteric modulatory nor (ant)agonistic 
properties at GABAA receptors. 
Radioligand binding assay for Na+ channel (site 
2) using [3H]batrachotoxin 
Affinity of TP-315 to sodium channels – site 2 
was expressed as a percentage of inhibition of the 
binding of [3H]batrachotoxin. Initially, TP-315 was 
tested in a screening assay at final concentration of 
100 µM and it was found to be very effective sodium 
channel blocker with %inhibition amounted to 92 ± 
4% (Table 1). Interestingly, carbamazepine, known as 
anti-epileptic drug acting on sodium channels, 
revealed much weaker inhibition of [3H]batrachotoxin 
binding (i.e. 17.4%). In the next step, radioligand 
binding assay was performed with varying 
concentrations of TP-315 in order to obtain 
dose-response curve (Fig. 4). Median inhibitory 
concentration (IC50) for TP-315 turned out to be 6.21 ± 
0.80 µM whereas IC50 for carbamazepine equalled 131 
µM. The other two reference substances, veratridine 
and lidocaine, inhibited the binding of 
[3H]batrachotoxin to a receptor site of sodium channel 
with IC50 of 16.7 ± 1.8 µM and 390 ± 126 µM, 
respectively. 
Interaction of TP-315 with orthosteric sites of 
human α7 and human α4β2 nicotinic 
acetylcholine receptors (nAChRs) 
Binding experiments were performed on 
membranes derived from HEK-293 and SH-SY5Y cells 
stably transfected with genes encoding human α4β2 
and human α7 nicotinic acetylcholine receptors 
(nAChRs). TP-315 at 100 µM concentration does not 
displace [3H]epibatidine from its complexes neither 
with hα4β2 nor hα7 nAChRs (Fig. 5). 
 
Table 1. Radioligand binding assay for Na+ channel (site 2) using [3H]batrachotoxin.  
 Sodium channel – site 2 (rat brain cortical membranes) 
Compounds % inhibition ± SEM at 100 µM IC50 ± SEM [µM] 
TP-315 92 ± 4 6.21 ± 0.80 
Veratridine 100 ± 2 16.7 ± 1.8 
Lidocaine 26 ± 2 390 ± 126 
Carbamazepine 17.41 1312 
Data represents the mean (± SEM) of two independent experiments, each conducted in duplicates. 
1data obtained from [9]; 2data obtained from [10] 
 





Figure 3. Influence of TP-315 on GABAA-receptor mediated currents; A. current recordings for electrophysiological agonist-mode screening experiments; B. 
dose-dependent influence of TP-315 on GABA-gated chloride current in HEK-293 cells expressing recombinant GABAA receptor (TP-315 used in combination with 
10 µM GABA). 
 
Influence of TP-315 on the viability of human 
HepG2 cells 
Human liver-derived cell lines are often used in 
drug development process for assessing safety of 
drug candidates. Toxicity of TP-315 was tested using 
immortalized hepatocellular carcinoma cells HepG2. 
The mentioned cell line constitutes one of the most 
frequently used model to study toxicity of drugs and 
chemicals [11-13]. In order to evaluate the viability of 
HepG2 cell after exposure to TP-315 PrestoBlue and 
ToxiLight assays were used. While PrestoBlue assay 
measures metabolic activity of cells (precisely, it 
measures cellular reducing activity), the ToxiLight 
assay was designed to measure cell membrane 
damage (i.e. it quantitatively measures the release of 
adenylate kinase from the membranes of damaged 
cells). The reference drug, astemizole, inhibited the 
viability of HepG2 cells in a dose-dependent manner. 
As its concentration increased from 1 µM to 100 µM 
the viability of cells decreased from 113% to 2% and 
from 93% to 14% in PrestoBlue and Toxilight assays, 
respectively (Table 2). At the same experimental 
conditions TP-315 used in the highest concentration of 
100 µM inhibited the growth of cells only by 6% (as 
measured in ToxiLight assay) and 15% (as measured 
in PrestoBlue assay). 






Figure 4. Dose – response binding curves for TP-315, veratridine and lidocaine obtained in [3H]batrachotoxin binding assay for Na+ channels – site 2. Graphs from 
two independent experiments performed in duplicates with mean IC50values ± SEM are shown. 
 
 
Figure 5. Displacement of [3H]epibatidine from its complexes with human α7 and human α4β2 nicotinic acetylcholine receptors (nAChRs). 
 
Table 2. Influence of different concentrations of TP-315 on the viability of human liver HepG2 cells using PrestoBlue and ToxiLight assays 
Type of assay PrestoBlue ToxiLight 
Viability (% of control) Viability (% of control) 
Concentration of compounds 100µM 50µM 10µM 1µM 100µM 50µM 10µM 1µM 
TP-315 75% 92% 103% 87% 94% 95% 95% 95% 




Molecular mechanisms of action of antiepileptic 
drugs (AEDs) are varied. Three main groups of 
mechanisms include: (i) modulation of ionchannels 
(sodium, calcium, potassium), (ii) enhancement of 
GABA-ergic (inhibitory) neurotransmission, and (iii) 
diminishing of glutamatergic (excitatory) 
neurotransmission. In case of manyAEDs, their 
activity is decided by more than one molecular 
mechanism. The chemical structure of TP-315, 
containing a five-membered 1,2,4-triazole ring, made 
it possible for the compound to have effect on GABAA 
receptors. When researching the antiepileptic effect of 
loreclezole Wingrove and co-workers proved that 
1,2,4-triazole ring of loreclezole interact with the 
amide group of Asn-289, which is situated on the β2 
subunit of the GABAA receptor [14]. Our previously 
conducted radioligand binding experiments with the 
use of radiolabeled ligands of GABAA receptor, i.e. 
[3H]muscimol and [3H]flunitrazepam, showed that 
4,5-disubstituted 1,2,4-triazole-3-thione derivatives 
did not possess the affinity to their respective active 
sites [15, 16]. The mentioned lack of affinity concerned 
both aromatic and aliphatic derivatives of 
1,2,4-triazole-3-thione. However, GABAA receptor 
complex contains many orthosteric and allosteric 
binding sites [17], and therefore, finding that there is 
no interaction between 4,5-disubstituted 
1,2,4-triazole-3-thiones and muscimol- and 
benzodiazepine-binding sites does not exclude the 
possibility of other effects on GABAA receptor. 




Therefore, in the course of searching for the 
mechanism of anticonvulsant activity of TP-315 we 
applied the patch clamp technique, that allows to 
investigate the influence of the compound on the 
chloride current through the GABAA receptor. It has 
been determined, during the electrophysiological 
experiments, that TP-315 did not cause any changes 
inchloride ion current. Moreover, it neither intensify 
nor inhibit GABA-evoked currents.Therefore, the 
obtained results justify the statement that TP-315 does 
not show the (ant)agonistic nor allosteric effect on 
GABAA receptor. 
The anticonvulsant activity of TP-315 was 
identified in the mouse maximal 
electroshock-induced seizure (MES) test, which is an 
experimental model of human generalized 
tonic-clonic seizures [18]. The MES-induced seizure 
test still remains one of the basic screening models 
used for the identification of new compounds 
showing anticonvulsant effects [19]. Numerous 
researches have proven that the anticonvulsant 
activity observed in the MES-induced seizure test is a 
result of interaction between the tested compound 
and voltage-gated sodium channels (VGSCs) [20]. In 
spite of such premises, the results presented herein 
provide the first experimental proof that TP-315 
shows strong affinity towards the VGSCs. TP-315 
displaced [3H]batrachotoxin from its binding site 
much stronger than veratridine and lidocaine. 
Moreover, TP-315 turned out to possess stronger 
affinity towards sodium channels than 
carbamazepine, the first generation AED acting on 
VGSCs. 
Sodium channels blockers, i.e. compounds 
disturbing the conduction of sodium ions through 
sodium channels, serve as local anaesthetics as well as 
antiarrhythmic and antiepileptic drugs. The quite new 
application of sodium channel blockers results from 
the fact that they are thought to inhibit excitotoxic 
damage of neurons [7]. Therefore they may show 
neuroprotective effects [21, 22]. Certainly, the 
hypothesis assuming that TP-315, beside the 
anticonvulsant activity, also shows neuroprotective 
effects shall require confirmation in experimental 
conditions. Nevertheless, in case of other AEDs acting 
on sodium channels, e.g. carbamazepine and 
phenytoin, the neuroprotective effects have been 
proven at the same time [23]. 
The research aiming at the understanding of 
molecular mechanism of action of TP-315 also 
included human α7 and human α4β2 nicotinic 
acetylcholine receptors (nAChRs). Although they do 
not belong to the main molecular targets of AEDs, the 
literature reports suggest that these receptors may 
play a significant role in pathophysiology of many 
neurological diseases, including epilepsy [24]. 
Significantly altered activity of nAChRs was observed 
in some types of epilepsy. This mainly concerns 
juvenile myoclonic epilepsy and autosomal dominant 
nocturnal frontal lobe epilepsy – ADNFLE [24]. 
Moreover, it has been found out that AEDs affect the 
function of nAChRs and that some of nAChRs 
antagonists show strong anticonvulsant effects in 
animal models of epilepsy [25]. For example, 
amino-alkyl-cyclohexanes efficiently protected mice 
and rats from seizures induced by electric shock (MES 
test) or nicotine. Median effective doses (ED50) for 
these derivatives reached 3.6 mg/kg in the MES test 
[26], and 2.46 mg/kg [25] in the nicotine-induced 
seizure model of epilepsy.  
During the present research, the affinity of 
TP-315 towards some of the nAChRs was tested using 
radioligand binding technique. During the 
experiments, the level of displacement of 
[3H]epibatidine from its complexes with α4β2 and α7 
receptors was measured. The mentioned receptors 
constitute the two main types of nicotinic 
acetylcholine receptors in the brain [27]. They differ in 
their sensibility to nicotine. Nicotine's affinity for 
human α4β2 nAChRs is nearly 1000 times higher than 
that for α7 receptor. It is also thought that 
nicotine-induced seizures are mediated mainly by α7 
nAChRs [28]. In the course of our experiments it has 
been found that TP-315 does not possess affinity to 
epibatidine-binding sites on human α4β2 and α7 
nAChRs. 
An important stage of the pre-clinical trials, the 
drug-candidates are subject to, is to check the effect of 
those compounds on human cells and tissues. 
Therefore, it is recommended that, at the stage of 
cytotoxicity testing, there are applied methods 
allowing determination of the tested compound’s 
effect on different phases of the cell cycle [29]. First of 
the two applied assays, i.e. PrestoBlue assay, 
measures the mitochondrial activity of cells, and 
therefore it is an early indicator of cellular toxicity. In 
turn, ToxiLight assay, whose principle consists in the 
measurement of adenylate kinase released from 
damaged cell membranes, is an indicator of cellular 
necrosis. Based on the results obtained from both 
PrestoBlue and ToxiLight assays it has been 
demonstrated that TP-315 is characterized by low 
toxicity for human hepatic HepG2 cells. While 
assessing the possible toxicity of drug-candidates, one 
should also observe the restrictions associated with in 
vitro methods. First of all, such methods measure the 
effect of chemical compounds on isolated cells, and 
therefore no interactions occurring in a living 
organism between different tissues and organs are 
taken into account.Therefore, it is worth mentioning 




that TP-315 was also tested in in-vivo model of 
neurotoxicity, i.e. in the chimney test [4]. The median 
toxic dose (TD50) for TP-315 administered 15min 
before the test was 462.9 ± 20.0 mg/kg, and the 
respective protective index (PI = TD50/ED50) value 
amounted to 9.7.  
Conclusions 
The presented study reports that the 
anticonvulsant activity of 5-(3-chlorophenyl)-4--
hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (TP-315) 
is at least the effect of its influence on the 
voltage-gated sodium channels (VGSCs). At the same 
time there has been excluded the possibility of 
interactions of TP-315 with orthosteric and allosteric 
binding sites on GABAA receptors.Moreover, it has 
been found that TP-315 does not interact with 
epibatidine-binding sites on human α4β2 and α7 
nAChRs. We also found that TP-315 affected the 
viability of human hepatic HepG2 cells to a slight 
degree only. The results obtained enabled to identify 
the plausible mechanism of action for TP-315. 
Moreover, the potent anticonvulsant activity together 
with low (neuro)toxicity, justify the further preclinical 
and hopefully clinical development of TP-315 as 
potential candidate for new antiepileptic drug. 
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